Medivation Acquisitions and Financial Impact

Medivation's acquisition journey began in 2016 when Pfizer acquired the company for $14 billion. This marked a significant milestone in the company's history.

Pfizer's acquisition of Medivation was a strategic move to expand its portfolio of cancer treatments. The acquisition allowed Pfizer to gain access to Medivation's flagship product, Xtandi, which was a key driver of the company's growth.

Xtandi's success was largely due to its ability to treat prostate cancer, a disease that affects millions of men worldwide. The medication's effectiveness in slowing the progression of the disease made it a valuable asset for Pfizer.

The acquisition had a significant financial impact on Pfizer, with the company reporting a net income of $15.9 billion in 2016, a 35% increase from the previous year.

If this caught your attention, see: Pfizer

Medivation was the target of a $14 billion buyout deal by Pfizer, outbidding Sanofi and Celgene.

Pfizer's offer was $81.50 per share, and it's expected to close in the third or fourth quarter of 2016.

Here's an interesting read: Pfizer UK

Medivation's pipeline isn't very big, but it's promising, with talazoparib in a later-stage trial for advanced breast cancer patients who have BRCA mutations.

The combination of Xtandi and talazoparib could be a uniquely value-added combination in the treatment of prostate cancer.

Pfizer believes the acquisition will build upon its success with Ibrance and its strong immuno-oncology portfolio, and transform Pfizer into a leading oncology company.

Pfizer just made a huge acquisition deal for $14 billion, buying out Medivation.

Medivation's Xtandi is a top-selling cancer treatment, with U.S. sales exceeding $1 billion in 2015 alone.

The deal is expected to close in the third or fourth quarter of 2016, with Pfizer offering $81.50 per share for all outstanding Medivation common stock.

Medivation's pipeline includes promising treatments for blood cancers, such as Pidiluzumab in mid-stage trials, and talazoparib in a later-stage trial for advanced breast cancer patients with BRCA mutations.

Talazoparib has the potential to be a game-changer in the treatment of prostate cancer, especially when combined with Xtandi.

Pfizer's Ibrance and Xtandi will give the company leadership in two hormone-driven cancers, prostate and breast cancer.

Pfizer acquired Wyeth for $68 billion in 2009, a massive deal that set a new standard for pharmaceutical mergers.

The $14 billion acquisition was a significant investment, but it pales in comparison to Pfizer's largest deal.

Pfizer's acquisition strategy has been a key driver of growth and innovation in the industry.

For another approach, see: Td Cowen Acquisition

Medivation is collaborating with Astellas Pharma Inc. to handle the development, manufacturing, and commercialization of XTANDI in the future.

The company has a license and supply agreement with CureTech for the development, manufacturing, and commercialization of its biologic molecules.

Medivation's clinical trials for prostate cancer include the Phase II trial, STRIVE, which is currently ongoing.

The Phase III trials, AFFIRM and PREVAIL, have already completed enrollment, while PROSPER and EMBARK are still enrolling participants.

TERRAIN is also part of the Phase II trial for prostate cancer.

Medivation is conducting Phase II clinical trials for breast cancer, including trials for AR+, ER+ or PgR+, HER2 Normal and TNBC, and HER2 Amplified and AR+.

The company has one commercial product on the market, XTANDI, which is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in the United States and Europe.

XTANDI's active ingredient is enzalutamide, an androgen receptor inhibitor.

Broaden your view: CEE Property Development Portfolio

Medivation doesn't anticipate paying any cash dividends on common stock in the foreseeable future.

Earnings will be used to finance the development and expansion of the business.